{"text": "Because the follow - up in these trials was less than 48 weeks after the end of the treatment , the possibility of a continued decrease in fibrosis among patients with a sustained virologic response should be evaluated with long - term histologic and virologic follow - up studies .", "label": "", "metadata": {}, "score": "42.770523"}
{"text": "Most notable were the statistically significant reductions in HbA1c levels at 30 days after only a single 200 mg dose of VRS-859 , which is predicted to have a reduction in HbA1c of 1.6 to 2.2 % at 6 months .", "label": "", "metadata": {}, "score": "43.28067"}
{"text": "Most of the differences were a 1 stage change : 16 % 1 stage and 4 % 2 or 3 stages for those biopsy pairs that improved ; 12 % 1 stage , and 3 % 2 or 3 stages for those that worsened .", "label": "", "metadata": {}, "score": "44.074883"}
{"text": "This is in contrast to median platelet counts rising to 36,000 microliters in the eltrombopag group after one week of treatment and ranging from 52,000 to 91,000 microliters for the remainder of the study .", "label": "", "metadata": {}, "score": "45.177242"}
{"text": "This is in contrast to median platelet counts rising to 36,000 microliters in the eltrombopag group after one week of treatment and ranging from 52,000 to 91,000 microliters for the remainder of the study .", "label": "", "metadata": {}, "score": "45.177242"}
{"text": "Furthermore , because the regression analyses were based solely on the results at the end of the 8-week DBP , the depth of the HRQL changes caused by increases in Hb may not have been fully revealed .", "label": "", "metadata": {}, "score": "45.477287"}
{"text": "Doses could be escalated to 8 mg once daily at 28 or 32 weeks at the investigator 's discretion when the patient presented more than six tender and swollen joints .", "label": "", "metadata": {}, "score": "45.56166"}
{"text": "Doses could be escalated to 8 mg once daily at 28 or 32 weeks at the investigator 's discretion when the patient presented more than six tender and swollen joints .", "label": "", "metadata": {}, "score": "45.56166"}
{"text": "\" The Phase 1 results in T2DM patients demonstrate that all doses administered ( up to 200 mg ) were well tolerated and no unexpected adverse events were noted .", "label": "", "metadata": {}, "score": "45.9521"}
{"text": "Activity improvement ranges from 73 % in patients receiving the PEG 1.5 and high - dose ribavirin combination to 39 % in patients treated by interferon 24 weeks ( Table 3 and Figure 3 ) .", "label": "", "metadata": {}, "score": "46.587036"}
{"text": "By 30 weeks , the initial glycemic responses noted at 14 weeks were not sustained .MK-0941 at one or more doses was associated with significant increases in the incidence of hypoglycemia , triglycerides , systolic blood pressure , and proportion of patients meeting criteria for predefined limits of change for increased diastolic blood pressure .", "label": "", "metadata": {}, "score": "47.79688"}
{"text": "About VRS-859The compound has been designed to provide improved therapeutic outcomes for T2DM patients including robust and sustained improvements in HbA1c , improved tolerability , prolonged half - life ( up to monthly dosing ) , as well as enhanced administration of a liquid formulation via a fine - gauge needle .", "label": "", "metadata": {}, "score": "48.180695"}
{"text": "About VRS-859The compound has been designed to provide improved therapeutic outcomes for T2DM patients including robust and sustained improvements in HbA1c , improved tolerability , prolonged half - life ( up to monthly dosing ) , as well as enhanced administration of a liquid formulation via a fine - gauge needle .", "label": "", "metadata": {}, "score": "48.180695"}
{"text": "[ 2 ] .In the long - term extension , the clinical improvements observed at week 24 were sustained through 52 weeks in RA patients .", "label": "", "metadata": {}, "score": "48.53227"}
{"text": "[ 2 ] .In the long - term extension , the clinical improvements observed at week 24 were sustained through 52 weeks in RA patients .", "label": "", "metadata": {}, "score": "48.53227"}
{"text": "Patients who demonstrated the greatest Hb increases from randomization to the end of the DBP also had the greatest improvements in HRQL during that time .", "label": "", "metadata": {}, "score": "48.70484"}
{"text": "For the regime with the worst sustained viral clearance rate ( of 5 % on interferon only for 24 weeks ) , 12 % of patients had an improved fibrosis score , 65 % remained unchanged , and 23 % deteriorated .", "label": "", "metadata": {}, "score": "48.845642"}
{"text": "In the present study , we also observed a reduction of fibrosis progression rates in comparison to estimates before treatment , especially among patients with initial significant fibrosis .", "label": "", "metadata": {}, "score": "49.213768"}
{"text": "Depending on individual platelet response , the dose of eltrombopag could be titrated within a range from 25 mg once daily to a maximum dose of 75 mg once daily .", "label": "", "metadata": {}, "score": "50.50318"}
{"text": "Depending on individual platelet response , the dose of eltrombopag could be titrated within a range from 25 mg once daily to a maximum dose of 75 mg once daily .", "label": "", "metadata": {}, "score": "50.50318"}
{"text": "These regimens given for 24 or 48 weeks allowed us to observe an improvement of necrosis and inflammation grades and a reduction of fibrosis progression at least during the 2 years ' histological follow - up .", "label": "", "metadata": {}, "score": "50.532097"}
{"text": "3 .Sustained response rates observed in the 10 different regimens .Activity improvement ranges from 73 % in patients receiving the PEG 1.5 and high dose ribavirin combination to 39 % in patients treated with interferon 24 weeks .", "label": "", "metadata": {}, "score": "50.559944"}
{"text": "When a sustained response was achieved , the histological impact was the same whatever the regimen : activity improvement was observed in 86 % of patients with only 7 % of patients with worsening fibrosis .", "label": "", "metadata": {}, "score": "51.157913"}
{"text": "Discussion .Recently published work by Afdhal et al .16 has demonstrated that weekly dosing with 40,000 units of epoetin alfa maintained the RBV dose and increased Hb levels in anemic HCV - infected patients undergoing combination therapy .", "label": "", "metadata": {}, "score": "51.2444"}
{"text": "Furthermore , the PK of VRS-859 in these patients was dose linear and comparable to the profile predicted from preclinical studies , validating the half - life extension capability of the XTEN technology and supporting a once monthly dosing regimen for VRS-859 .", "label": "", "metadata": {}, "score": "51.2582"}
{"text": "These increases were statistically significant in 7 of the 8 domains of the SF-36 , as well as in all three categories measured by the LASA .", "label": "", "metadata": {}, "score": "51.260155"}
{"text": "Seventy T2DM patients concurrently on metformin were enrolled in the study : 18 patients received placebo and 52 patients received one of six dose levels : 12.5 , 25 , 50 , 100 , 150 and 200 mg .", "label": "", "metadata": {}, "score": "51.74376"}
{"text": "\" We are very encouraged by the robust results seen in this initial Phase 1 study , most notably the statistically significant reductions in HbA1c levels at 30 days after only a single 200 mg dose of VRS-859 , \" commented Dr. Cleland .", "label": "", "metadata": {}, "score": "51.747444"}
{"text": "An acceptable dose of platelets could be within 25 percent ( lower or higher ) of the target dose .Patients were prophylactically transfused on days when platelet counts were less than or equal to 10,000 microliters .", "label": "", "metadata": {}, "score": "51.92897"}
{"text": "An acceptable dose of platelets could be within 25 percent ( lower or higher ) of the target dose .Patients were prophylactically transfused on days when platelet counts were less than or equal to 10,000 microliters .", "label": "", "metadata": {}, "score": "51.92897"}
{"text": "Patients who received Peg 1.5- RBV 48 weeks : 73 % improved or stabilized fibrosis , 27 % worsened ; 18 % improved , 55 % stabilized .", "label": "", "metadata": {}, "score": "52.1115"}
{"text": "Treatment dose did not affect the frequency of any bleeding grade in any of the four patient groups .This is the first worldwide randomized study showing that one - quarter to one - third of all platelet transfusions were given unnecessarily in the past and can be reduced in the future without any harm to patients following high - dose chemotherapy and autologous stem cell transplantation , according to Dr. Wandt .", "label": "", "metadata": {}, "score": "52.253387"}
{"text": "Treatment dose did not affect the frequency of any bleeding grade in any of the four patient groups .This is the first worldwide randomized study showing that one - quarter to one - third of all platelet transfusions were given unnecessarily in the past and can be reduced in the future without any harm to patients following high - dose chemotherapy and autologous stem cell transplantation , according to Dr. Wandt .", "label": "", "metadata": {}, "score": "52.253387"}
{"text": "3 .The improved Hb levels relative to randomization attained by both treatment groups by the end of the OLP were maintained during the continuation of the OLP .", "label": "", "metadata": {}, "score": "52.260025"}
{"text": "Secondary objectives included safety , duration of leukopenia and thrombocytopenia , and the number of red blood cell transfusions .Platelet transfusions were significantly reduced by 27 percent in the experimental arm as compared with the traditional arm .", "label": "", "metadata": {}, "score": "52.45091"}
{"text": "2 , 7 In these studies , patients receiving epoetin alfa treatment for their anemia not only experienced an increase in Hb but also exhibited clinically significant improvements in HRQL domains such as energy , activity , and overall quality of life .", "label": "", "metadata": {}, "score": "52.470768"}
{"text": "The Phase 1 multicenter , blinded , placebo - controlled , single - ascending dose study was designed to evaluate the safety and tolerability of VRS-859 as well as the ability to maintain glycemic control for one month in T2DM patients after a single dose .", "label": "", "metadata": {}, "score": "52.658928"}
{"text": "To measure the drug 's safety , bleeding symptoms were prospectively evaluated using the WHO Bleeding Scale .Patients who received eltrombopag were eight times more likely to achieve platelet counts of 50,000 to 400,000 microliters during the six - month treatment period as compared with those in the placebo arm .", "label": "", "metadata": {}, "score": "52.67988"}
{"text": "To measure the drug 's safety , bleeding symptoms were prospectively evaluated using the WHO Bleeding Scale .Patients who received eltrombopag were eight times more likely to achieve platelet counts of 50,000 to 400,000 microliters during the six - month treatment period as compared with those in the placebo arm .", "label": "", "metadata": {}, "score": "52.67988"}
{"text": "In the present study , interferon monotherapy for 24 weeks was associated with an improvement of activity grade in 37 % and a worsening of fibrosis stage in 24 % of treated patients .", "label": "", "metadata": {}, "score": "52.803078"}
{"text": "Sustained response rates observed in the 10 different regimens .The sustained response rate varied significantly from 5 % to 63 % according to regimen .", "label": "", "metadata": {}, "score": "52.839016"}
{"text": "2 A ) .In addition , patients with Hb increases of 2 g / dL or more had an increase of 17 to 22 mm on the 3 constructs measured by the LASA ( Fig .", "label": "", "metadata": {}, "score": "53.03627"}
{"text": "I 'll stick to this dose for a year or so and make gradual changes .If i were to make a change however , it would be from NO DAC to DAC for my CJC1295 .", "label": "", "metadata": {}, "score": "53.814754"}
{"text": "This double - blind , multicenter , phase III study found that long - term eltrombopag therapy compared with placebo treatment significantly increased platelet counts , decreased bleeding symptoms , allowed for a reduction of baseline ITP therapy , and reduced the use of rescue medications in previously treated patients with chronic ITP .", "label": "", "metadata": {}, "score": "53.93515"}
{"text": "I 'm 5 ' 11 about 200lbs .I keep seeing a dose schedule of 100mcg , 3 times a day , morning , bedtime and either pre or post workout ?", "label": "", "metadata": {}, "score": "53.97427"}
{"text": "Study drugs were identical in appearance and were packaged in identical containers .The initial dose of the study drug was 40,000 units of subcutaneously weekly ; this dose or matching placebo was titrated to 60,000 units weekly if Hb levels did not increase by 1 g / dL from randomization after 4 weeks of study drug treatment had been completed .", "label": "", "metadata": {}, "score": "54.163445"}
{"text": "In this group , ITT and PP sustained response rates were 56 percent and 59 percent , respectively .No clinical or laboratory factors predictive of a sustained response were identified in the study .", "label": "", "metadata": {}, "score": "54.74315"}
{"text": "In this group , ITT and PP sustained response rates were 56 percent and 59 percent , respectively .No clinical or laboratory factors predictive of a sustained response were identified in the study .", "label": "", "metadata": {}, "score": "54.74315"}
{"text": "The primary efficacy end point was change from baseline in A1C at Week 14 .RESULTS At Week 14 , A1C and 2-h postmeal glucose ( PMG ) improved significantly versus placebo with all MK-0941 doses .", "label": "", "metadata": {}, "score": "54.936073"}
{"text": "All these pivotal trials were prospectively similarly designed with identical and centralized histologic and viral methods .As there was no randomized group without treatment , the first approved regimen ( standard interferon alpha 2b 3 MU TIW 24 weeks ) was considered as a control group and the other 9 regimens as \" reinforced .", "label": "", "metadata": {}, "score": "56.124565"}
{"text": "Results from the assessment tools were checked immediately for thoroughness and completion , and attempts were made to capture missing information within 3 days of the office visit .", "label": "", "metadata": {}, "score": "56.234177"}
{"text": "The results of the current analyses further suggest that increases in Hb are independently associated with increases in HRQL in HCV - infected patients , with the largest Hb increases producing the greatest improvements in HRQL .", "label": "", "metadata": {}, "score": "56.481842"}
{"text": "Thanks .Good advice .200mcg together with GRF 1 - 29 modified ( 150mcg ) before bed is good .If dosing three times a day ( best routine ) then take post work out as you want to add to the GH pulse you got from the work out .", "label": "", "metadata": {}, "score": "56.7054"}
{"text": "Patients received either 4 mg or 8 mg once - daily doses of baricitinib beginning at week 24 through week 52 .In the initial 12-week treatment duration , patients received one of four doses of baricitinib ( 1 mg , 2 mg , 4 mg or 8 mg ) or placebo , administered once daily .", "label": "", "metadata": {}, "score": "56.881508"}
{"text": "Patients received either 4 mg or 8 mg once - daily doses of baricitinib beginning at week 24 through week 52 .In the initial 12-week treatment duration , patients received one of four doses of baricitinib ( 1 mg , 2 mg , 4 mg or 8 mg ) or placebo , administered once daily .", "label": "", "metadata": {}, "score": "56.881508"}
{"text": "Nonresponders : 17 % improved , 62 % stabilized , 21 % worsened .Rates for Peg 1.5 plus RBV high dose were better than low dose RBV .", "label": "", "metadata": {}, "score": "57.166115"}
{"text": "In this study , the experimental strategy was compared with a traditional preventive transfusion strategy in which patients received a transfusion if platelet counts were less than or equal to 10/nL. The researchers concluded that the experimental strategy was both cost effective and safe in this patient population .", "label": "", "metadata": {}, "score": "57.2272"}
{"text": "In the experimental arm , 46 percent of patients did not need any platelet transfusions , compared with 22 percent of patients in the traditional arm .", "label": "", "metadata": {}, "score": "57.243984"}
{"text": "The primary objective of the study was the reduction of platelet transfusions by 15 to 25 percent .Secondary objectives included safety , duration of leukopenia and thrombocytopenia , and the number of red blood cell transfusions .", "label": "", "metadata": {}, "score": "57.48115"}
{"text": "Because many patients were unchanged in their fibrosis score , the calculated post - treatment fibrosis progression rate was 0 in a significant proportion .This highlights the difficulty of comparing the pre- and post - treatment fibrosis progression rates .", "label": "", "metadata": {}, "score": "57.57459"}
{"text": "One patient developed hemolytic anemia while receiving epoetin alfa during the OLP , despite RBV dose adjustment ; this patient received a transfusion and recovered without further sequelae .", "label": "", "metadata": {}, "score": "57.580482"}
{"text": "In this study , the experimental strategy was compared with a traditional preventive transfusion strategy in which patients received a transfusion if platelet counts were less than or equal to .", "label": "", "metadata": {}, "score": "57.70664"}
{"text": "The long - term extension of the JADA study evaluated the efficacy and s ..As previously reported in the initial 12-week portion of this study ...", "label": "", "metadata": {}, "score": "57.723953"}
{"text": "The long - term extension of the JADA study evaluated the efficacy and s ..As previously reported in the initial 12-week portion of this study ...", "label": "", "metadata": {}, "score": "57.723953"}
{"text": "Disease Improvement / Activity Measure24-WeekResponders / Total Patients ( Percent Responders)52-WeekResponders / Total Patients ( Percent Responders)ACR20 .47/195 ( 24%)DAS28 ESR .", "label": "", "metadata": {}, "score": "58.096397"}
{"text": "Disease Improvement / Activity Measure24-WeekResponders / Total Patients ( Percent Responders)52-WeekResponders / Total Patients ( Percent Responders)ACR20 .47/195 ( 24%)DAS28 ESR .", "label": "", "metadata": {}, "score": "58.096397"}
{"text": "The vitality and social functioning domain scores showed even greater improvement , increasing 15 to 20 points after epoetin alfa treatment .It is important to note that HRQL improves in HCV - infected patients who achieve an SVR 25 ; therefore , viral clearance may have contributed to the HRQL changes observed with epoetin alfa treatment in this study .", "label": "", "metadata": {}, "score": "58.205536"}
{"text": "Table 2 .Impact of PEG interferon and ribavirin combination regimen on fibrosis progression between baseline and posttreatment biopsies SVRs : 25 % improved fibrosis , 68 % stabilized , and & worsened .", "label": "", "metadata": {}, "score": "58.396152"}
{"text": "This argues against the concept of stopping treatment too early in patients without a sustained virologic response .The antifibrotic and histologic efficacy of these regimens should be carefully considered before prematurely stopping treatment , especially in patients who have significant fibrosis .", "label": "", "metadata": {}, "score": "58.43467"}
{"text": "Grade 4 bleeding , the most serious , was seen in 3 percent , 2 percent , and 2 percent of patients in the low - dose , medium - dose , and high - dose arms , respectively .", "label": "", "metadata": {}, "score": "58.502502"}
{"text": "Grade 4 bleeding , the most serious , was seen in 3 percent , 2 percent , and 2 percent of patients in the low - dose , medium - dose , and high - dose arms , respectively .", "label": "", "metadata": {}, "score": "58.502502"}
{"text": "With an appropriate study design , it might be possible to separate the HRQL improvements due to a direct central nervous system effect of epoetin alfa treatment from the improvements attributable to a rise in Hb .", "label": "", "metadata": {}, "score": "58.84252"}
{"text": "Impact of the 10 different regimens on fibrosis stage .Fibrosis worsening ranged from 8 % in patients receiving the PEG 1.5 and ribavirin high dose combination to 23 % in patients treated with interferon for 24 weeks .", "label": "", "metadata": {}, "score": "59.4235"}
{"text": "A recent study by McHutchison and colleagues 12 examined treatment adherence in HCV - infected patients receiving combination therapy for 24 to 48 weeks .A similar analysis of patients receiving PEG - IFN alfa-2b plus RBV showed that dose reductions of RBV alone or in combination with PEG - IFN significantly affected the early virological response rate .", "label": "", "metadata": {}, "score": "59.79103"}
{"text": "Another method of examining the data was to compare the calculated fibrosis progression rate before and after each treatment .Both estimates assume linearity , which may not be correct .", "label": "", "metadata": {}, "score": "59.873417"}
{"text": "17 Post hoc analyses comparing HRQL in study patients with and without cirrhosis were performed at baseline , week 5 , and the conclusion of the DBP .", "label": "", "metadata": {}, "score": "60.065666"}
{"text": "aStandard interferon 3 million units 3 times per week for 24 weeks was considered as the control regimen and the other regimen as reinforced regimen .", "label": "", "metadata": {}, "score": "60.066982"}
{"text": "Histologic response according to regimen Between randomized different treatment arms there was a significant difference in 2 separate trials for activity grade improvement in favor of interferon - ribavirin 48 weeks in comparison with interferon alone 48 weeks or 24 weeks ( Tables 2 and 3 ) .", "label": "", "metadata": {}, "score": "60.126236"}
{"text": "The implication is that this will be associated with improvements in long - term clinical outcome in terms of morbidity and mortality , but such data are not yet reported .", "label": "", "metadata": {}, "score": "60.354897"}
{"text": "Significant improvement in HRQL was also seen in patients with Hb increases of 0 to 2 g / dL. These patients demonstrated an increase of 0.5 to 7 points across all domains of the SF-36 , and an increase of 6 to 10 mm in all constructs of the LASA .", "label": "", "metadata": {}, "score": "60.42578"}
{"text": "Between regimens there were also highly significant differences .Fibrosis worsening ranged from 8 % in patients receiving the PEG 1.5 and ribavirin high - dose .", "label": "", "metadata": {}, "score": "60.434196"}
{"text": "When compared with the other variables in the model , Hb was also the most stable and consistent predictor for HRQL improvement across all domains .", "label": "", "metadata": {}, "score": "60.529434"}
{"text": "It seems unfair not to take into account information based on 17 years of disease evolution .The fibrosis stage at the first biopsy for each patient represents an excellent abstract of this balance between extracellular matrix formation and degradation .", "label": "", "metadata": {}, "score": "60.585114"}
{"text": "The Phase 1 Trial The primary objective of the study was to determine the safety and tolerability of a single subcutaneous dose of VRS-859 in patients with T2DM .", "label": "", "metadata": {}, "score": "60.912315"}
{"text": "Mean number of weeks of combination therapy prior to first dose of study drug ( \u00b1SD , range ) .Comparison of HRQL in HCV - Infected Patients With Population Norms .", "label": "", "metadata": {}, "score": "60.991894"}
{"text": "However , the first approved regimen ( interferon 3 MU TIW for 24 weeks ) had already an impact on the natural history of chronic hepatitis C as demonstrated in meta - analysis of randomized trials21 and in historical or randomized comparisons .", "label": "", "metadata": {}, "score": "61.019325"}
{"text": "A total of 197 patients with platelet counts less than 30,000 microliters were stratified by splenectomy status , use of baseline ITP medication , and platelets of less than or equal to 15,000 microliters .", "label": "", "metadata": {}, "score": "61.207428"}
{"text": "The RBV dose was to be reduced during the study when the Hb level fell below 10 g / dL and discontinued when it fell below 8.5 g / dL. These recommendations for RBV dosing were provided as guidelines only ; final decisions regarding RBV dose adjustments were made by the investigators after complete assessment of patients ' individual clinical situations .", "label": "", "metadata": {}, "score": "61.22775"}
{"text": "Mean Hb levels from randomization through the 6-month follow - up period ; mean weekly epoetin alfa dose ( units ) from randomization through the conclusion of combination therapy .", "label": "", "metadata": {}, "score": "61.27878"}
{"text": "This is a great approach and my fav .I prefer CJC-1295 DAC as my GHRH .Anyway use GHRP-2 through the day due to high gh spike and shorter active life .", "label": "", "metadata": {}, "score": "61.76468"}
{"text": "This is a great approach and my fav .I prefer CJC-1295 DAC as my GHRH .Anyway use GHRP-2 through the day due to high gh spike and shorter active life .", "label": "", "metadata": {}, "score": "61.76468"}
{"text": "There were no reported SAEs in the study .Adverse events , including those related to GI tolerability , were primarily mild and transient .These results support the company 's plan to conduct a 6-month repeat dose study to determine a safe and efficacious subcutaneous dose of VRS-859 in patients with T2DM .", "label": "", "metadata": {}, "score": "62.082764"}
{"text": "Some patients in the dexamethasone - only arm who failed to achieve a sustained response and had platelet counts of less than or equal to 20 x 109/L following 30 days of therapy up to the end of six months received a salvage ( rescue ) treatment of rituximab plus dexamethasone .", "label": "", "metadata": {}, "score": "62.08619"}
{"text": "The end point was the percentage of patients with significant fibrosis at the second biopsy .Evolution of activity ( necrosis and inflammation ) was analyzed by assessing for each regimen the percentage of patients who improve by at least 1-grade activity , remain stable , or worsen by at least 1 grade .", "label": "", "metadata": {}, "score": "62.131866"}
{"text": "This is not a trivial difference , especially considering that 20 % of the patients enrolled in the epoetin alfa group had already reduced their dose of RBV prior to entering the study .", "label": "", "metadata": {}, "score": "62.20057"}
{"text": "There was a significant association between fibrosis and activity changes but with low concordance rates in all patients .This was also observed in nonresponders ( data not shown ) .", "label": "", "metadata": {}, "score": "62.631424"}
{"text": "Alcohol consumption was not assessed during the treatment and follow - up periods in all of these trials .This is a limitation of the present study .", "label": "", "metadata": {}, "score": "62.642494"}
{"text": "One grade in METAVIR is equivalent to 4 grades in the Knodell index .This is twice the usual definition of histological improvement .If there were more reversal versus the control regimen this would strongly suggest an even more significant effect versus an absence of treatment .", "label": "", "metadata": {}, "score": "62.92177"}
{"text": "This effect was most prominent in patients who achieved a virologic response , which is best achieved by the combination of PEG - interferon and high - dose ribavirin .", "label": "", "metadata": {}, "score": "63.332836"}
{"text": "The last approved regimen , the PEG - interferon and high - dose ribavirin combination , had the highest histological benefit ever observed : an activity improvement was observed in 73 % of patients and a worsening of fibrosis stage was observed in only 8 % .", "label": "", "metadata": {}, "score": "63.41768"}
{"text": "Trial DesignThis randomized , open - label , long - term extension of Phase 2b JADA study included 201 ( 95 percent ) of the eligible 212 patients .", "label": "", "metadata": {}, "score": "63.96763"}
{"text": "Trial DesignThis randomized , open - label , long - term extension of Phase 2b JADA study included 201 ( 95 percent ) of the eligible 212 patients .", "label": "", "metadata": {}, "score": "63.96763"}
{"text": "Furthermore , the pooling of data was possible because all the 4 trials were designed prospectively together with centralized endpoints , and all known prognostic factors were taken into account in univariate and multivariate analyses .", "label": "", "metadata": {}, "score": "64.07401"}
{"text": "3 , 10 , 11 In this study , epoetin alfa treatment improved both of these factors and therefore has the potential to increase patient adherence to the combination regimen .", "label": "", "metadata": {}, "score": "64.18504"}
{"text": "This report extends a previous similar study of 1509 chronic HCV patients6 but concentrates more on the effects of antiviral treatment on patients with established cirrhosis .", "label": "", "metadata": {}, "score": "64.54387"}
{"text": "500mcg ipamorelin + 100mcg cjc1295 no DAC was proven through serum hgh blood work to increase serum hgh to 12.1 with a much longer sustained elevation that other gh peptides , up to 3 1/2 hours I believe .", "label": "", "metadata": {}, "score": "64.647316"}
{"text": "Progression of fibrosis was analyzed by 3 methods First , we compared the impact of the different treatment regimens on the percentage of patients who improve by at least 1 fibrosis stage , remained stable , or worsened by at least 1 stage .", "label": "", "metadata": {}, "score": "64.90159"}
{"text": "These estimates have been extensively detailed and validated previously .The fibrosis progression rate after treatment was defined as the ratio between the difference in fibrosis stage expressed in METAVIR units between the 2 biopsies ( before and after treatment ) and the interval between the 2 biopsies in years .", "label": "", "metadata": {}, "score": "65.08928"}
{"text": "In the 8-week DBP , eligible patients were randomized to treatment with 40,000 units of epoetin alfa ( PROCRIT , Ortho Biotech Products , L.P. , Bridgewater , NJ ) weekly or matched placebo .", "label": "", "metadata": {}, "score": "65.62745"}
{"text": "Regression analysis demonstrated that Hb change was a significant independent predictor of HRQL change in all constructs of the LASA and in 6 of 8 domains of the SF-36 .", "label": "", "metadata": {}, "score": "65.7103"}
{"text": "The retrospective analyses of these randomized trials suggested 2 options for maintenance therapy , either PEG-1.0 monotherapy which is the simplest and well - tolerated regimen or the combination PEG-0.5-ribavirin , which was the most effective regimen in nonresponders on necrosis and inflammation .", "label": "", "metadata": {}, "score": "65.72101"}
{"text": "Hb improvement was an independent predictor of HRQL improvement in these patients .In conclusion , epoetin alfa provided clinically significant HRQL improvement in HCV - infected patients receiving IFN / RBV therapy .", "label": "", "metadata": {}, "score": "66.01391"}
{"text": "In addition , data from the safety portion of this trial indicated that epoetin alfa treatment not only maintained Hb levels for the duration of HCV combination therapy , it also did not adversely affect HCV RNA clearance .", "label": "", "metadata": {}, "score": "66.06427"}
{"text": "116/194 ( 60%)Boolean Remission .32/194 ( 16 % ) Safety ResultsSafety signals observed during the open - label extension were consistent with previously reported results of baricitinib .", "label": "", "metadata": {}, "score": "66.080826"}
{"text": "116/194 ( 60%)Boolean Remission .32/194 ( 16 % ) Safety ResultsSafety signals observed during the open - label extension were consistent with previously reported results of baricitinib .", "label": "", "metadata": {}, "score": "66.080826"}
{"text": "The authors have addressed these difficulties by looking at their data in a number of different ways to determine if the same trends are observed with each approach .", "label": "", "metadata": {}, "score": "66.10504"}
{"text": "Table 4 .Impact of PEG - interferon and ribavirin combination regimen on fibrosis progression rate .NOTE .Impact was analyzed according to treatment regimen , baseline fibrosis stage and virologic response , in naive patients with known duration of infection .", "label": "", "metadata": {}, "score": "66.18643"}
{"text": "However , the regimens were randomized , which precluded a major risk of bias .A bias related to patient 's selection could be reasonably excluded , as there were no different characteristics between all patients randomized versus patients who had paired biopsies .", "label": "", "metadata": {}, "score": "66.62213"}
{"text": "Safety .Patients were followed for safety throughout the DBP and OLP as described previously .16 Patients remaining on epoetin alfa after the conclusion of the 8-week OLP were monitored for safety through the completion of their epoetin alfa and HCV combination therapy .", "label": "", "metadata": {}, "score": "66.66751"}
{"text": "Mean laboratory parameters , including total bilirubin , alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase , and gamma glutamyltransferase remained within the normal range from the conclusion of the OLP to the conclusion of HCV treatment .", "label": "", "metadata": {}, "score": "66.79134"}
{"text": "Mean change in SF-36 and LASA scores by Hb change during the DBP .( A ) Change in SF-36 scores in patients with Hb decrease , Hb increase of 0 to 2 g / dL , and Hb increase of 2 g / dL or more .", "label": "", "metadata": {}, "score": "67.00874"}
{"text": "However , as with any pharmaceutical product , there are substantial risks and uncertainties in the process of development and commercialization .There is no guarantee that future study results and patient experience will be consistent with study findings to date , that the product will receive regulatory approval , or , if approved , that the product will be commercially successful .", "label": "", "metadata": {}, "score": "67.15715"}
{"text": "However , as with any pharmaceutical product , there are substantial risks and uncertainties in the process of development and commercialization .There is no guarantee that future study results and patient experience will be consistent with study findings to date , that the product will receive regulatory approval , or , if approved , that the product will be commercially successful .", "label": "", "metadata": {}, "score": "67.15715"}
{"text": "In a trial of patients not in the United States , these percentages were 28 % , 28 % , and 32 % , respectively .", "label": "", "metadata": {}, "score": "67.3362"}
{"text": "I did 500mcg the first night and got really bad insomnia , so i lowered to 300mcg and no insomnia i will stay at this dose for a week then up to 400mcg see how things go , also post the articles or PM the link .", "label": "", "metadata": {}, "score": "67.34381"}
{"text": "To minimize bias , the study protocol specified that these questionnaires be completed before any other study - related procedures were performed or test results given .", "label": "", "metadata": {}, "score": "67.58032"}
{"text": "Because of the nonnormal distribution of these estimates and the uncertainty of linearity , only medians and nonparametric tests were used .In a previous study , we had validated our estimate by comparison with paired biopsy estimates ( our cohort and meta - analysis of control groups ) .", "label": "", "metadata": {}, "score": "67.59683"}
{"text": "In chronic ITP , low blood platelet counts persist unless treated and can last for an indefinite amount of time .A total of 197 patients with platelet counts less than 30,000 microliters were stratified by splenectomy status , use of baseline ITP medication , and platelets of less than or equal to 15,000 microliters .", "label": "", "metadata": {}, "score": "67.66641"}
{"text": "Ten different regimens combining standard interferon , PEG interferon , and ribavirin were compared .All regimens significantly reduced the fibrosis progression rates in comparison to rates before treatment .", "label": "", "metadata": {}, "score": "67.8099"}
{"text": "Fortunately , the last decade has witnessed major improvements in our ability to treat this disease , with progressive improvements in the rates of viral clearance accompanied by normalization of transaminases and improvements in necro - inflammatory scores on liver histology .", "label": "", "metadata": {}, "score": "68.058235"}
{"text": "At baseline , 2243 patients had no significant fibrosis ( 75 % ) and 767 significant fibrosis ( 25 % ) , 673 ( 22 % ) had no significant activity , and 2337 ( 78 % ) significant activity .", "label": "", "metadata": {}, "score": "68.17052"}
{"text": "Statistical Analyses .This estimation was based on results obtained in an earlier proof - of - principle , randomized , open - label , multicenter study of epoetin alfa treatment of anemic HCV - infected patients on combination therapy .", "label": "", "metadata": {}, "score": "68.19212"}
{"text": "For patients with METAVIR fibrosis stages 2 , 3 , and 4 at initial biopsy , the fibrosis progression rate before treatment was 0.137 compared with -0.488 after treatment .", "label": "", "metadata": {}, "score": "68.262886"}
{"text": "After completion of the OLP , score disparities in all domains between the study population and the other populations narrowed considerably , with scores of the study population actually surpassing those of other groups in certain domains .", "label": "", "metadata": {}, "score": "68.43156"}
{"text": "Best responses in patients receiving Peg 1,5 plus high dose RBV .Table 3 .Impact of PEG interferon and ribavirin combination regimen on activity progression between baseline and posttreatment biopsies .", "label": "", "metadata": {}, "score": "68.48378"}
{"text": "17 By the conclusion of the OLP , these disparities had narrowed , with the scores of study patients on the SF-36 domain of vitality surpassing those of patients who had clinical depression .", "label": "", "metadata": {}, "score": "68.53688"}
{"text": "I 'm also still at 25 % bf so , I know I need to be focusing on my diet and cardio to make the real changes .", "label": "", "metadata": {}, "score": "68.541565"}
{"text": "A quantitative reverse - transcription multicycle polymerase chain reaction was used , with a lower limit of detection of 50 IU / mL ( 100 copies / mL ) .", "label": "", "metadata": {}, "score": "68.5983"}
{"text": "Figure 1 .Study design ( adapted with permission from Afdhal et al .16 ) .HRQL , health - related quality of life ; IFN , interferon alfa ; RBV , ribavirin ; DBP , double - blind phase ; OLP , open - label phase ; SC , subcutaneously ; Hb , hemoglobin .", "label": "", "metadata": {}, "score": "68.86084"}
{"text": "These data show that the HRQL of anemic HCV - infected patients receiving combination therapy is lower than that of the general population , untreated HCV - infected patients , and individuals with other chronic conditions .", "label": "", "metadata": {}, "score": "68.86167"}
{"text": "Compared with our prior analyses , a new factor , the body mass index , was strongly associated with fibrosis progression even after adjustment for the 3 main factors previously identified , viral response , fibrosis stage , and age .", "label": "", "metadata": {}, "score": "69.18677"}
{"text": "This study permitted us to identify body mass index as a major factor associated with significant fibrosis even in treated patients .There are at least 2 factors explaining this association .", "label": "", "metadata": {}, "score": "69.502"}
{"text": "These imbalances could possibly account for some of the differences in SVR .Although the results of this study do not indicate that epoetin alfa improves SVR , they clearly provide support for additional studies with adequate sample size to determine if adjuvant epoetin alfa therapy is associated with a statistically significant improvement in SVR .", "label": "", "metadata": {}, "score": "70.17517"}
{"text": "Significantly fewer patients treated with eltrombopag experienced any bleeding or clinically significant bleeding throughout the study as compared with those in the placebo arm .Additionally , more patients in the eltrombopag arm were able to stop or reduce other ITP medication and required less rescue therapy compared with those in the placebo group .", "label": "", "metadata": {}, "score": "70.81525"}
{"text": "Significantly fewer patients treated with eltrombopag experienced any bleeding or clinically significant bleeding throughout the study as compared with those in the placebo arm .Additionally , more patients in the eltrombopag arm were able to stop or reduce other ITP medication and required less rescue therapy compared with those in the placebo group .", "label": "", "metadata": {}, "score": "70.81525"}
{"text": "Mean HRQL scores of anemic HCV - infected patients receiving combination therapy at randomization were significantly lower than those of both the general population and patients who had other chronic conditions .", "label": "", "metadata": {}, "score": "70.83778"}
{"text": "This multicenter phase III study is the first to prospectively determine that adding the immunotherapy drug rituximab to dexamethasone ( a steroid that is a standard therapy for ITP ) is safe and effective in adult patients with previously untreated idiopathic thrombocytopenic purpura ( ITP ) .", "label": "", "metadata": {}, "score": "71.05497"}
{"text": "( B ) Percentage of patients with undetectable levels of HCV RNA , stratified by treatment status ( treatment - na\u00efve or treatment - experienced ) , from randomization through 6 months after the completion of epoetin alfa and HCV combination therapy .", "label": "", "metadata": {}, "score": "71.30062"}
{"text": "Post hoc analyses comparing the SF-36 HRQL values of study patients at randomization were compared with norms of other patient populations , 17 , 20 using independent sample t tests .", "label": "", "metadata": {}, "score": "71.53607"}
{"text": "25 Neary MP , Cort S , Bayliss MS , Ware JE .Sustained virologic response is associated with improved health - related quality of life in relapsed chronic hepatitis C patients .", "label": "", "metadata": {}, "score": "72.47727"}
{"text": "Known side effects of this regimen include not only anemia , but also fatigue , myalgia , flu - like symptoms , clinical depression , and alterations in concentration , mood , and libido .", "label": "", "metadata": {}, "score": "72.5649"}
{"text": "J Clin Oncol 2001 ; 19 : 2875 - 2882 .3 Bernstein D , Kleinman L , Barker CM , Revicki DA , Green J .", "label": "", "metadata": {}, "score": "72.612785"}
{"text": "Patients and Methods .Study Design .As previously reported by Afdhal et al ., 16 patients were eligible for enrollment in this study if they had developed anemia while receiving HCV combination therapy ( either first course of treatment or retreatment for previous relapse or nonresponse ) .", "label": "", "metadata": {}, "score": "72.667915"}
{"text": "The results of this study indicate that this treatment regimen could be an effective option prior to splenectomy for some patients as well as a possible cure for others .", "label": "", "metadata": {}, "score": "72.735176"}
{"text": "Impact of PEG Interferon and Ribavirin Combination Regimen in Patients Without Sustained Virologic Response ( Nonresponders or Relapsers ) on Activity Progression Between Baseline and Posttreatment Biopsies .", "label": "", "metadata": {}, "score": "72.80255"}
{"text": "Impact of PEG Interferon and Ribavirin Combination Regimen in Patients Without Sustained Virologic Response ( Nonresponders or Relapsers ) on Fibrosis Progression Between Baseline and Posttreatment Biopsies .", "label": "", "metadata": {}, "score": "72.817184"}
{"text": "Effects of Prophylactic Platelet Dose on Transfusion Outcomes ( PLADO Trial ) [ Abstract # 285 ] Sherrill J. Slichter , MD , Puget Sound Blood Center for the National Heart , Lung , and Blood Institute Transfusion Medicine / Hemostasis Clinical Trials Network , Seattle , WA .", "label": "", "metadata": {}, "score": "73.05406"}
{"text": "Epoetin alfa therapy in the anemic HCV - infected population successfully increased Hb and provided patients with a clinically significant improvement in HRQL .Acknowledgements . 2 Gabrilove JL , Cleeland CS , Livingston RB , Sarokhan B , Winer , E , Einhorn LH .", "label": "", "metadata": {}, "score": "73.079155"}
{"text": "MK-0941 was associated with an increased incidence of hypoglycemia and elevations in triglycerides and blood pressure .Footnotes .G.E.M. and M.A. are currently affiliated with Johnson & Johnson Pharmaceutical Research & Development , Raritan , New Jersey .", "label": "", "metadata": {}, "score": "73.25207"}
{"text": "The researchers examined the results for all enrolled patients , regardless of whether or not they completed the study ( intention - to - treat basis , ITT ) , and on a per - protocol ( PP ) basis , examining those who had completed the treatment regimen .", "label": "", "metadata": {}, "score": "73.61008"}
{"text": "The researchers examined the results for all enrolled patients , regardless of whether or not they completed the study ( intention - to - treat basis , ITT ) , and on a per - protocol ( PP ) basis , examining those who had completed the treatment regimen .", "label": "", "metadata": {}, "score": "73.61008"}
{"text": "Adherence to RBV therapy , in particular , has been shown to significantly impact SVR ; recent data suggest that the reduction of RBV dose alone during the first 12 to 20 weeks of treatment results in a significant decrease in SVR rates in a retreatment population .", "label": "", "metadata": {}, "score": "74.02404"}
{"text": "To take into account the sampling error we compared the biopsy sizes between groups .RESULTS Of the 4493 naive patients enrolled in the 4 trials , 3010 had paired biopsies available with a 20-month mean duration between the biopsies ( Table 1 ) .", "label": "", "metadata": {}, "score": "74.02407"}
{"text": "Each individual site enrolled participants who were assigned a patient number in strict sequential order according to the patient number on the study drug container .", "label": "", "metadata": {}, "score": "74.77602"}
{"text": "The size of the biopsies ( at baseline or at the second biopsy ) were not different between patients with or without cirrhosis reversal .Among the 75 patients with cirrhosis reversal , the second biopsy sample was graded stage 3 in 23 patients , stage 2 in 26 , stage 1 in 23 , and no fibrosis in 3 .", "label": "", "metadata": {}, "score": "74.82665"}
{"text": "NOTE .Poynard trial has 3 arms : interferon - ribavirin 48 weeks , interferon - ribavirin 24 weeks , and interferon 48 weeks .McHutchison trials has same 3 arms plus 24-week interferon therapy .", "label": "", "metadata": {}, "score": "74.8845"}
{"text": "Grade 2 bleeding is clinically significant bleeding that does not require a red blood cell transfusion .Grade 2 or higher bleeding occurred in 71 percent of patients in the low - dose arm , 69 percent in the medium - dose arm , and 70 percent in the high - dose arm .", "label": "", "metadata": {}, "score": "75.18646"}
{"text": "Grade 2 bleeding is clinically significant bleeding that does not require a red blood cell transfusion .Grade 2 or higher bleeding occurred in 71 percent of patients in the low - dose arm , 69 percent in the medium - dose arm , and 70 percent in the high - dose arm .", "label": "", "metadata": {}, "score": "75.18646"}
{"text": "Safety .The results of the safety analyses of the DBP and OLP have been previously reported .16 A total of 20 serious adverse events occurred during the study , with 8 occurring during the continuation of the OLP ( week 17 and thereafter ) .", "label": "", "metadata": {}, "score": "75.45511"}
{"text": "Dig Dis Sci 1997 ; 42 : 2482 - 2486 .6 McHutchison JG , Ware , JE , Bayliss MS , Pianko S , Albrecht JK , Cort S , et al .", "label": "", "metadata": {}, "score": "75.5202"}
{"text": "Aliment Pharmacol Ther 2002 ; 16 : 1633 - 1639 .12 McHutchison JG , Manns M , Patel K , Poynard T , Lindsay KL , Trepo C , et al .", "label": "", "metadata": {}, "score": "75.578445"}
{"text": "J Hepatol 2001 ; 34 : 140 - 147 .7 Crawford J , Cella D , Cleeland CS , Cremieux PY , Demetri GD , Sarokhan BJ , et al .", "label": "", "metadata": {}, "score": "75.96434"}
{"text": "Each new trial included in its design the previous standard regimen .The PEG interferon monotherapy trial was started in 1997 , before the end of the standard interferon - ribavirin combination trials in 1998 .", "label": "", "metadata": {}, "score": "76.15358"}
{"text": "\" Symptoms can include bruising , nose bleeds , bleeding in the mouth , and rash - like spots on the skin .If left untreated , thrombocytopenia can become a life - threatening condition when blood platelet counts fall below 5,000 microliters because the risk of serious hemorrhaging ( excessive bleeding ) increases .", "label": "", "metadata": {}, "score": "76.345764"}
{"text": "Gastroenterology 2004 ; 126 : 1015 - 1023 .15 Hadziyannis SJ , Sette H , Morgan TR , Balan V , Diago M , Marcellin P , et al .", "label": "", "metadata": {}, "score": "76.5695"}
{"text": "In virologic nonresponders , there was less fibrosis regression and more fibrosis progression than in responders .However , it may be incorrect to conclude that the combination regimen or interferons alone are valueless in virologic nonresponders .", "label": "", "metadata": {}, "score": "76.59717"}
{"text": "Changes in hemoglobin during interferon alfa-2b plus ribavirin therapy for chronic hepatitis C viral infection .J Viral Hepat 2004 ; 11 : 243 - 250 .", "label": "", "metadata": {}, "score": "76.599106"}
{"text": "The study was initiated on November 1 , 2001 ; the OLP concluded on November 22 , 2002 ; and the follow - up phase concluded on November 6 , 2003 .", "label": "", "metadata": {}, "score": "76.72394"}
{"text": "This augurs well for the future of our patients with chronic HCV infection , particularly if they clear the virus with treatment .This study also encourages further scientific investigation of the key cell and molecular mechanisms of liver fibrosis and raises the prospect that an antifibrotic agent aimed at promoting regression of disease may be an important therapeutic strategy for the future .", "label": "", "metadata": {}, "score": "76.84032"}
{"text": "This study consisted of two treatment phases , followed by a 6-month safety monitoring period .The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institutional review committees of the investigators ' respective institutions or central institutional review board .", "label": "", "metadata": {}, "score": "76.91688"}
{"text": "13 N. Gara , M. G. Ghany , What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin , Clinical Infectious Diseases , 2013 , 56 , 11 , 1629 CrossRef .", "label": "", "metadata": {}, "score": "77.18738"}
{"text": "Epoetin alfa maintains ribavirin dose in HCV - infected patients : a prospective , double - blind , randomized controlled study .Gastroenterology 2004 ; 126 : 1302 - 1311 .", "label": "", "metadata": {}, "score": "77.30799"}
{"text": "However , there was no difference in biopsy sizes between patients with cirrhosis reversal and those whose biopsies did not change .If we analyzed stage 3 and stage 4 together , there was also a very significant improvement rate in fibrosis in 50 % of cases ( data not shown ) .", "label": "", "metadata": {}, "score": "77.31882"}
{"text": "Regression models treated Hb change as either a continuous or a categorical variable .Multicollinearity for the variables in the regression model was evaluated prior to regression analysis .", "label": "", "metadata": {}, "score": "77.48854"}
{"text": "The effect of these new regimens on histological changes has not been well characterized .The aim of this study was to compare the efficacy of these different regimens ( PEG - interferon alone or in combination with ribavirin ) on fibrosis progression and on the necrosis and inflammatory features and to identify risk factors for these changes .", "label": "", "metadata": {}, "score": "77.85109"}
{"text": "Study Population Mean Randomization SF-36 Scores Compared With Norms of Other Populations .Comparison of HRQL in Patients With and Without Cirrhosis .Liver biopsy reports were available for 164 patients .", "label": "", "metadata": {}, "score": "77.93309"}
{"text": "No opportunistic infections or tuberculosis cases were observed .There was one death in the 8 mg group due to a suspected myocardial infarction . \" In this clinical trial baricitinib showed statistically and clinically significant improvements in the features of this condition , which were maintained throughout a year of treatment .", "label": "", "metadata": {}, "score": "78.045654"}
{"text": "No opportunistic infections or tuberculosis cases were observed .There was one death in the 8 mg group due to a suspected myocardial infarction . \" In this clinical trial baricitinib showed statistically and clinically significant improvements in the features of this condition , which were maintained throughout a year of treatment .", "label": "", "metadata": {}, "score": "78.045654"}
{"text": "HEPATOLOGY 2002 ; 35 : 704 - 708 .4 Ware JE Jr , Bayliss MS , Mannocchia M , Davis GL .Health - related quality of life in chronic hepatitis C : impact of disease and treatment response .", "label": "", "metadata": {}, "score": "78.145935"}
{"text": "VRS-859 , a long - acting glucagon - like peptide-1 ( GLP-1 ) analog , is being developed as a once monthly treatment for patients with type 2 diabetes mellitus ( T2DM ) .", "label": "", "metadata": {}, "score": "78.267746"}
{"text": "VRS-859 , a long - acting glucagon - like peptide-1 ( GLP-1 ) analog , is being developed as a once monthly treatment for patients with type 2 diabetes mellitus ( T2DM ) .", "label": "", "metadata": {}, "score": "78.267746"}
{"text": "22 Manns MP , McHutchison JG , Gordon SC , Rustgi VK , Shiffman M , Reindollar R , et al .Peg - interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for intial treatment of chronic hepatitis C : a randomized trial .", "label": "", "metadata": {}, "score": "78.27806"}
{"text": "One highly experienced pathologist , blinded to knowledge of the treatment regime , using the METAVIR scoring system , assessed all liver biopsy specimens .This methodology has been reported to yield a high degree of reproducibility in the assessment of fibrosis.7 Moreover , the vast numbers of patients under analysis would mean that errors caused by sampling or inconsistent scoring of liver fibrosis are likely to be equally distributed across groups .", "label": "", "metadata": {}, "score": "78.29289"}
{"text": "Once - weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus - infected patients receiving ribavirin plus interferon alfa .", "label": "", "metadata": {}, "score": "78.32919"}
{"text": "11 Decreased HRQL has also been associated with the discontinuation of therapy in HCV - infected individuals .3 It is possible , in a manner similar to the situation with cancer patients receiving chemotherapy , that treatment to increase Hb levels in HCV - infected patients receiving IFN / RBV or PEG - IFN / RBV combination therapy may improve HRQL .", "label": "", "metadata": {}, "score": "78.33502"}
{"text": "this could explain why on certain nights i get only 5 1/2 hours sleep yet feel great in the AM .No Prami , fell back to sleep easily , and did have dreams , i always wake up awesome refreshed like i had 8 hours of striaght sleep .", "label": "", "metadata": {}, "score": "78.46774"}
{"text": "An understanding of the cell and molecular mechanisms involved in the process of reversibility of liver fibrosis are therefore of major importance and may point the way forward to new therapeutic strategies that attempt to mimic or promote this process .", "label": "", "metadata": {}, "score": "78.475296"}
{"text": "In the control group there were no cases of an improvement in cirrhosis , which compared with 75 of 153 cases ( 49 % ) in the reinforced regimes .", "label": "", "metadata": {}, "score": "78.5824"}
{"text": "If left untreated , thrombocytopenia can become a life - threatening condition when blood platelet counts fall below 5,000 microliters because the risk of serious hemorrhaging ( excessive bleeding ) increases .", "label": "", "metadata": {}, "score": "78.85635"}
{"text": "HEPATOLOGY 1999 ; 30 : 550 - 555 .5 Hunt CM , Dominitiz JA Bute BP , Waters B , Blasi U , Williams DM .", "label": "", "metadata": {}, "score": "78.95755"}
{"text": "The impact on fibrosis was related both to the response to therapy and the duration of interferon treatment .Recently , it has been shown that the pegylated form of interferon ( PEG - interferon ) has a significantly higher efficacy in achieving sustained response in comparison to standard interferon .", "label": "", "metadata": {}, "score": "79.09042"}
{"text": "24 Patrick DL , Gagnon DD , Zagari MJ , Mathijs R , Sweetenham J .Epoetin Alfa Study Group .Assessing the clinical significance of health - related quality of life ( HrQOL ) improvements in anaemic cancer patients receiving epoetin alfa .", "label": "", "metadata": {}, "score": "79.145164"}
{"text": "But first , are we sure that the observations of Poynard et al . are correct , or could there have been any confounding factors ?", "label": "", "metadata": {}, "score": "79.344444"}
{"text": "Cancer 2002 ; 95 : 888 - 895 . 8 Rebetron ( Rebetol / Intron A ) [ package insert].Kenilworth , NJ : Schering Corporation , 2003 .", "label": "", "metadata": {}, "score": "79.456024"}
{"text": "The study authors and press program moderator will be available for interviews after the press conference or by telephone .Additional press briefings will take place throughout the meeting on combating blood clots , treatment advances in leukemia and lymphoma , improvements in stem cell therapies , and advances in screening and treatment for sickle cell disease .", "label": "", "metadata": {}, "score": "79.81201"}
{"text": "The study authors and press program moderator will be available for interviews after the press conference or by telephone .Additional press briefings will take place throughout the meeting on combating blood clots , treatment advances in leukemia and lymphoma , improvements in stem cell therapies , and advances in screening and treatment for sickle cell disease .", "label": "", "metadata": {}, "score": "79.81201"}
{"text": "You can find out more about our use of cookies in About Cookies , including instructions on how to turn off cookies if you wish to do so .", "label": "", "metadata": {}, "score": "80.026955"}
{"text": "The PP group included 38 patients treated with dexamethasone alone and 26 treated with rituximab / dexamethasone .ITT and PP sustained response rates were 63 percent and 85 percent in the rituximab / dexamethasone combination arm as compared with 36 percent and 39 percent in the dexamethasone - alone arm .", "label": "", "metadata": {}, "score": "80.16377"}
{"text": "The PP group included 38 patients treated with dexamethasone alone and 26 treated with rituximab / dexamethasone .ITT and PP sustained response rates were 63 percent and 85 percent in the rituximab / dexamethasone combination arm as compared with 36 percent and 39 percent in the dexamethasone - alone arm .", "label": "", "metadata": {}, "score": "80.16377"}
{"text": "Against this background , it is interesting that Poynard et al .found that cirrhosis was more likely to reverse in younger patients , which led them to suggest that early cirrhosis may reverse more readily than established disease .", "label": "", "metadata": {}, "score": "80.200966"}
{"text": "One death occurred during this period ( the patient with esophageal and gastric variceal bleeds ) .Figure 4 .Percentage of patients with undetectable HCV RNA throughout the study and follow - up period .", "label": "", "metadata": {}, "score": "80.69976"}
{"text": "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection .N Engl J Med 2002 ; 347 : 975 - 982 .11 Gaeta GB , Precone DF , Felaco FM , Bruno R , Spadaro A , Stomaiuolo G , et al .", "label": "", "metadata": {}, "score": "80.78585"}
{"text": "23 to be represented by an increase in SF-36 domain scores of 3 to 5 points .Ware et al .17 suggested that an increase of 10 points exerted a moderate effect on patients ' HRQL .", "label": "", "metadata": {}, "score": "80.99179"}
{"text": "Ipamorelin Dose ?Got some Ipamorelin that will arive in a few days and confused about all the different dose 's and times that I 've researched .", "label": "", "metadata": {}, "score": "81.02042"}
{"text": "Gastroenterology 2002 ; 123 : 1061 - 1069 .13 Davis GL , Wong JB , McHutchison JG , Manns MP , Harvey J , Albrecht J .", "label": "", "metadata": {}, "score": "81.09157"}
{"text": "Before a generalized conclusion that cirrhosis can be cured , several limitations of our study must be underlined .Cirrhosis reversal was defined as a change in fibrosis score based on the biopsy sample .", "label": "", "metadata": {}, "score": "81.164734"}
{"text": "The duration of leukopenia and the need for red blood cell transfusions were the same in both arms .Oral Eltrombopag for the Long - Term Treatment of Patients With Chronic Idiopathic Thrombocytopenic Purpura ( ITP ) : Results of a Phase III , Double - Blind , Placebo - Controlled Study [ Abstract # 400 ] Gregory Cheng , Chinese University of Hong Kong , Hong Kong , China .", "label": "", "metadata": {}, "score": "81.287506"}
{"text": "I did n't do it for long though .But 500mcg is a nice amount to go with your GHRH of chose .200mcg will still give great effects but I think Ipam truly shines when you go a bit higher .", "label": "", "metadata": {}, "score": "81.46138"}
{"text": "I did n't do it for long though .But 500mcg is a nice amount to go with your GHRH of chose .200mcg will still give great effects but I think Ipam truly shines when you go a bit higher .", "label": "", "metadata": {}, "score": "81.46138"}
{"text": "An international , multicenter , randomized , controlled study , BMC Gastroenterology , 2012 , 12 , 1 , 11 CrossRef .18 Cara L. Mack , Regino P. Gonzalez - Peralta , Nitika Gupta , Daniel Leung , Michael R. Narkewicz , Eve A. Roberts , Philip Rosenthal , Kathleen B. Schwarz , NASPGHAN Practice Guidelines , Journal of Pediatric Gastroenterology and Nutrition , 2012 , 54 , 6 , 838 CrossRef .", "label": "", "metadata": {}, "score": "81.745865"}
{"text": "For example , can disease regress to the extent that the liver returns to complete normality ?The Poynard et al .report suggests that this occurred in 3 patients who had established cirrhosis on their first biopsy .", "label": "", "metadata": {}, "score": "82.05141"}
{"text": "Patients were excluded if they had HBV or human immunodeficiency virus infection , a daily alcohol consumption greater than 50 g , or other forms of liver disease ( hemochromatosis , autoimmune , 1-antitrypsin , steatohepatitis ) .", "label": "", "metadata": {}, "score": "82.065506"}
{"text": "The difference between grades must therefore be interpreted accordingly .For example , grade 4 does not mean that there is twice as much fibrosis as grade 2 .", "label": "", "metadata": {}, "score": "82.49423"}
{"text": "HEPATOLOGY 2003 ; 38 : 645 - 652 .14 Shiffman M , Di Bisceglie AM , Lindsay KL , Morishima C , Wright EC , Everson GT , et al .", "label": "", "metadata": {}, "score": "82.49611"}
{"text": "HCV - infected individuals receiving treatment for their disease had a lower randomization HRQL than both healthy controls and patients with chronic diseases such as diabetes mellitus , chronic depression , and congestive heart failure .", "label": "", "metadata": {}, "score": "82.651886"}
{"text": "Jeffrey L. Cleland , Ph.D. , Diartis Chief Executive Officer , was present at the poster session to discuss the recently completed safety , pharmacokinetic ( PK ) and pharmacodynamics ( PD ) results from the company 's Phase 1 clinical trial in T2DM patients .", "label": "", "metadata": {}, "score": "82.99866"}
{"text": "No Prami , fell back to sleep easily , and did have dreams , i always wake up awesome refreshed like i had 8 hours of striaght sleep .", "label": "", "metadata": {}, "score": "83.49461"}
{"text": "The \" reversal \" of cirrhosis ( change in fibrosis score based on the biopsy sample ) was observed in 75 patients ( 49 % ) , none in the control regimen ( Table 8) .", "label": "", "metadata": {}, "score": "84.02072"}
{"text": "There ... .Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open - Label , Long - Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis . ...", "label": "", "metadata": {}, "score": "84.301254"}
{"text": "PROMPT study , which seeks to advance understanding of the hereditary risks for certain ... .( Date:2/9/2016 ) ...This market research report on the global ... of the market in terms of revenue ( USD Million ) . ...", "label": "", "metadata": {}, "score": "84.34921"}
{"text": "After diagnosis , type 2 diabetes patients are often placed on a diet and exercise program to control blood glucose levels and reduce body weight , but these patients usually progress to oral drug therapy , metformin and/or sulfonylurea .", "label": "", "metadata": {}, "score": "84.40457"}
{"text": "7 EASL Clinical Practice Guidelines : Management of hepatitis C virus infection , Journal of Hepatology , 2014 , 60 , 2 , 392 CrossRef .", "label": "", "metadata": {}, "score": "84.77815"}
{"text": "Conclusions : PEG - interferon and ribavirin combination significantly reduces the rate of fibrosis progression in patients with hepatitis C. Background Approximately 170 million people worldwide are infected with chronic hepatitis C virus ( HCV ) .", "label": "", "metadata": {}, "score": "84.92763"}
{"text": "Most of the complications related to chronic infection occurs in patients who have established cirrhosis .Treatments that could halt or diminish the progression of fibrosis would theoretically be beneficial .", "label": "", "metadata": {}, "score": "85.12629"}
{"text": "The combination of PEG - interferon and ribavirin eradicates the virus in more than 50 % of patients , and therefore potentially can prevent cirrhosis , amplifying our previous results with standard interferon plus ribavirin combination .", "label": "", "metadata": {}, "score": "85.92342"}
{"text": "20 EASL Clinical Practice Guidelines : Management of hepatitis C virus infection , Journal of Hepatology , 2011 , 55 , 2 , 245 CrossRef Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open - Label , Long - Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis . ...", "label": "", "metadata": {}, "score": "85.95166"}
{"text": "I agree .I think Ipamorelin would be great for most people not just bodybuilders .Good luck with your cycle I am excited to get mine ... should be very soon .", "label": "", "metadata": {}, "score": "86.17137"}
{"text": "Diartis acquired the VRS-859 ( exenatide - XTEN ) program from Versartis , Inc. and continues its development for T2DM .XTEN is a novel hydrophilic sequence of natural amino acids and is expressed as a fusion protein with a therapeutically active peptide or protein .", "label": "", "metadata": {}, "score": "86.77321"}
{"text": "It was just a short article I wrote for a newsletter .It 's in my thread ' Ipamorelin ' on the first page .Thanks .", "label": "", "metadata": {}, "score": "87.21834"}
{"text": "Abstract .Anemia and decreased health - related quality of life ( HRQL ) are common in patients receiving combination therapy of interferon alfa ( IFN ) and ribavirin ( RBV ) for chronic hepatitis C virus ( HCV ) infection .", "label": "", "metadata": {}, "score": "87.873665"}
{"text": "A sampling error can not explain the significant association between cirrhosis reversal and virologic response and activity improvement .The patients with cirrhosis reversal were younger , and it is possible that early cirrhosis is easier to reverse than more established cirrhosis .", "label": "", "metadata": {}, "score": "87.93843"}
{"text": "Apoptosis of activated HSCs is also decreased in mice that are transgenic for mutated collagen I that is resistant to the effects of MMPs .These studies indicate that the key events in the regression of liver fibrosis are interlinked and include apoptosis of HSCs , decreased expression of TIMP-1 , increased MMP activity , increased degradation of collagen I , and altered HSC - matrix interactions .", "label": "", "metadata": {}, "score": "87.94116"}
{"text": "A common theme in all of these reports is an effective therapeutic intervention that either removes or effectively suppresses the underlying disease process .Reversibility of cirrhosis was reported over 30 years ago in patients with hemochromatosis after long - term intensive venesection therapy.8 Improvements in liver fibrosis and cirrhosis have also been reported in patients with autoimmune chronic active hepatitis and primary biliary cirrhosis11 after effective immunosuppressive therapy .", "label": "", "metadata": {}, "score": "88.482956"}
{"text": "As yet , it is not known which of these events is the primary regulatory factor , but these observations have opened up the prospect of novel therapeutic strategies for the treatment of liver fibrosis by trying to initiate regression via these pathways .", "label": "", "metadata": {}, "score": "88.4978"}
{"text": "The bed time dose makes me hungry an hour later ill raid the fridge , good when i was bulking but trying to trim down now so i am switch the bed time dose to .", "label": "", "metadata": {}, "score": "89.10657"}
{"text": "All of these problems were considered and addressed in the study .Sampling error is a perennial problem , but is less likely to be relevant in a disease such as HCV if liver biopsy specimens are of an adequate size .", "label": "", "metadata": {}, "score": "89.36565"}
{"text": "OBJECTIVE To assess the efficacy and safety of MK-0941 , a glucokinase activator ( GKA ) , when added to stable - dose insulin glargine in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "89.59645"}
{"text": "A complete list of MK-0941 Study 007 investigators can be found in the Supplementary Data online .University of California , San Diego School of Medicine .", "label": "", "metadata": {}, "score": "89.61337"}
{"text": "Ann Intern Med 2004 ; 140 : 346 - 355 .16 Afdhal NH , Dieterich DT , Pockros PJ , Schiff ER , Shiffman ML , Sulkowski MS , et al .", "label": "", "metadata": {}, "score": "89.97157"}
{"text": "About Diabetes Treatment Treatment of diabetes involves lowering blood glucose levels .Despite the availability of current therapies , more than 60 percent of people with diabetes do not achieve their target levels with their current treatment regimen .", "label": "", "metadata": {}, "score": "90.01544"}
{"text": "I think it is worthwhile rotating GHRP 's but there is a big place for Ipamorelin .Out of all the GHRP 's I have used I feel best on Ipamorelin .", "label": "", "metadata": {}, "score": "90.37936"}
{"text": "The study is ongoing , with all patients who are continuing in the study receiving baricitinib 4 mg once daily .About JAK InhibitionThere are four known JAK enzymes : JAK1 , JAK2 , JAK3 and TYK2 .", "label": "", "metadata": {}, "score": "90.81972"}
{"text": "The study is ongoing , with all patients who are continuing in the study receiving baricitinib 4 mg once daily .About JAK InhibitionThere are four known JAK enzymes : JAK1 , JAK2 , JAK3 and TYK2 .", "label": "", "metadata": {}, "score": "90.81972"}
{"text": "( Date:2/11/2016 ) ... , Feb. 11 , 2016 NanoViricides , Inc. ... it has entered into an agreement with the ... nanoviricides \u00ae drug candidates in standard animal models of ... , Research Director .", "label": "", "metadata": {}, "score": "90.92218"}
{"text": "There are data consistent with this suggestion in patients with chronic HBV infection treated with lamivudine .Serial biopsies performed in these patients demonstrated that expression of smooth muscle actin ( an indirect measure of the number of activated HSCs ) was decreased as liver fibrosis improved after lamivudine treatment .", "label": "", "metadata": {}, "score": "91.190056"}
{"text": "Lilly and Incyte undertake no duty to update forward - looking statements .P - LLY .[ 1 ] E. Keystone , P. Taylor , M. Genovese , D. Schlichting , S. Beattie , C. Gaich , R. Fidelus Gort , M. Luchi , W.L. Macias .", "label": "", "metadata": {}, "score": "91.41765"}
{"text": "Lilly and Incyte undertake no duty to update forward - looking statements .P - LLY .[ 1 ] E. Keystone , P. Taylor , M. Genovese , D. Schlichting , S. Beattie , C. Gaich , R. Fidelus Gort , M. Luchi , W.L. Macias .", "label": "", "metadata": {}, "score": "91.41765"}
{"text": "Jim brings nearly 25 years ... and procurement , having spent nearly two decades in ...Chain / Logistics and Procurement at Genzyme and , most recently ... .", "label": "", "metadata": {}, "score": "91.467026"}
{"text": "Manns trial has 3 arms : PEG 1.5 -ribavirin 48 weeks , PEG 0.5 -ribavirin 48 weeks , and interferon - ribavirin 48 weeks .There was no significant difference between randomized arms in a single trial .", "label": "", "metadata": {}, "score": "91.90106"}
{"text": "If this is your first visit , be sure to check out the FAQ by clicking the link above .You may have to register before you can post : click the register link above to proceed .", "label": "", "metadata": {}, "score": "92.058975"}
{"text": "Your feedback is important to us , so please let us know if you have comments or ideas for improvement .Health - related quality of life ( HRQL ) is impaired in many disease states ranging from diabetes mellitus 1 to cancer .", "label": "", "metadata": {}, "score": "92.45568"}
{"text": "One pathologist ( Zachary Goodman ) reviewed the biopsies at the time these individual studies were undertaken without any information concerning the clinical , biological , or treatment characteristics during the conduct of each study .", "label": "", "metadata": {}, "score": "92.561714"}
{"text": "3 However , published data have suggested that HCV - infected patients have a decreased HRQL compared with the general population .4 Studies have shown that HCV - infected patients who did not have cirrhosis but who were receiving treatment had a decreased HRQL when compared with groups of healthy individuals and patients infected with hepatitis B virus .", "label": "", "metadata": {}, "score": "92.84725"}
{"text": "Arthritis and Rheumatism .2012 ; 64(10(supp)):S1049 .[ 3 ] S. Verstovsek .Therapeutic potential of JAK2 inhibitors .American Society of Hematology .( Date:2/10/2016 ) ... ...", "label": "", "metadata": {}, "score": "92.85837"}
{"text": "Arthritis and Rheumatism .2012 ; 64(10(supp)):S1049 .[ 3 ] S. Verstovsek .Therapeutic potential of JAK2 inhibitors .American Society of Hematology .( Date:2/10/2016 ) ...", "label": "", "metadata": {}, "score": "93.07262"}
{"text": "Should i take the IPAMORELIN a half hour before my prebed meal ?Or should i take it an hour after my prebed meal ?Old thread i know ( LOL i 'll probably get neg rep points for posting here ) .", "label": "", "metadata": {}, "score": "93.44095"}
{"text": "Secondly , there is a strong relationship between fibrosis progression and metabolism .Recently , we observed that the liver fibrosis risk was increased in overweight patients particularly when the body mass index was greater than 27.28 Since the beginning of these pivotal studies the mean weight is increasing particularly in patients in the United States .", "label": "", "metadata": {}, "score": "93.497086"}
{"text": "Methods The individual data from 4 randomized trials of PEG - interferon alfa-2b alone ( Pegintron , Schering Plough , Kenilworth , NJ),8 or in combination with ribavirin , or of the combination interferon alfa-2b and ribavirin ( Rebetron , Schering Plough ) were obtained .", "label": "", "metadata": {}, "score": "93.60769"}
{"text": "February 11 , 2016 , ...From March ...Academy of Dermatology Annual Meeting at the Walter E. Washington Convention Center in ... for both the condition of hyperhidrosis ( excessive sweating ) and its treatment options .", "label": "", "metadata": {}, "score": "94.05281"}
{"text": "Cytokines such as interleukin-6 , -12 and -23 and both type 1 and type 2 interferons signal through these pathways .JAK - dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases , suggesting that JAK inhibitors may be useful for the treatment of a broad range of inflammatory conditions .", "label": "", "metadata": {}, "score": "94.21347"}
{"text": "Cytokines such as interleukin-6 , -12 and -23 and both type 1 and type 2 interferons signal through these pathways .JAK - dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases , suggesting that JAK inhibitors may be useful for the treatment of a broad range of inflammatory conditions .", "label": "", "metadata": {}, "score": "94.21347"}
{"text": "It provides hematologist - approved information about these common blood conditions including risk factors , preventive measures , and treatment options .A cornerstone of this public awareness campaign is a new documentary by award - winning filmmaker Joseph Lovett called \" Blood Detectives , \" which will air on the Discovery Health cable network on December 19 , 2008 , at 7:00 p.m. ET / PT and again at 12:00 midnight .", "label": "", "metadata": {}, "score": "95.0555"}
{"text": "17 The LASA is a patient - reported instrument that has been used extensively to evaluate HRQL in anemic patients and addresses three major constructs : activity level , energy level , and overall quality of life .", "label": "", "metadata": {}, "score": "95.18377"}
{"text": "The fate of these cells and the mechanisms by which fibrotic matrix is removed have been studied in animal models of reversibility of liver fibrosis .", "label": "", "metadata": {}, "score": "95.57015"}
{"text": "2016 Checkpoint Inhibitors for Cancer - ...Are you interested in the future of cancer ... inhibitors .Visiongain , s report gives those predictions to 2026 ... level .", "label": "", "metadata": {}, "score": "95.684265"}
{"text": "The suggestion that liver fibrosis and cirrhosis are reversible is not a novel concept , but large - scale clinical trials in the treatment of chronic hepatitis C are making this concept more widely known and generally acceptable , thus helping to complete an important paradigm shift in hepatology .", "label": "", "metadata": {}, "score": "96.65424"}
{"text": "3 EASL Recommendations on Treatment of Hepatitis C 2015 , Journal of Hepatology , 2015 , 63 , 1 , 199 CrossRef .4 Zobair M. Younossi , Maria Stepanova , Stanislas Pol , Jean - Pierre Bronowicki , Maria Patrizia Carrieri , Marc Bourli\u00e8re , The impact of ledipasvir / sofosbuvir on patient - reported outcomes in cirrhotic patients with chronic hepatitis C : the SIRIUS study , Liver International , 2015 , n / a Wiley Online Library .", "label": "", "metadata": {}, "score": "96.82443"}
{"text": "Baricitinib is in Phase III development as a potential treatment for rheumatoid arthritis .It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy .", "label": "", "metadata": {}, "score": "96.8468"}
{"text": "Baricitinib is in Phase III development as a potential treatment for rheumatoid arthritis .It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy .", "label": "", "metadata": {}, "score": "96.8468"}
{"text": ", The Human Vaccines Project brings together ... .( Date:2/10/2016 ) ... , Feb. 10 , 2016 Matchbook , Inc. , ... for fast growing biotech companies , announced today the ...", "label": "", "metadata": {}, "score": "96.85525"}
{"text": "Apoptosis of activated HSCs was also observed after decompressive surgery in the bile duct ligation model of liver injury .In the regression phase , fibrotic liver matrix is degraded and removed as a consequence of the action of metalloproteinases , including MMP-1 , MMP-2 , and MMP-14 , and this occurs in part because of a rapid decrease in expression of metalloproteinase inhibitors , such as TIMP-1 .", "label": "", "metadata": {}, "score": "97.37594"}
{"text": "February 11 , 2016 , ...The book , \" Computers Should ... services , what questions to ask your IT consultant before signing a contract and how ... computer network . , \" With companies relying heavily on e - mail and technology , it 's more important ... .", "label": "", "metadata": {}, "score": "97.95062"}
{"text": "I have written articles on all 3 so I will post them up now if anyone is interested .Ipam is incredible when you boom dose it .", "label": "", "metadata": {}, "score": "98.29831"}
{"text": "I have written articles on all 3 so I will post them up now if anyone is interested .Ipam is incredible when you boom dose it .", "label": "", "metadata": {}, "score": "98.29831"}
{"text": "( Date:2/10/2016 ) ... ...February 10 , 2016 , ... ... as the World Molecular Imaging Congress ( WMIC ) , will be held in New York ... meeting is \" Imaging Biology ... Improving Therapy .", "label": "", "metadata": {}, "score": "98.350174"}
{"text": "In September , ASH launched Blo o d : The Vital C o nnection .It provides hematologist - approved information about these common blood conditions including risk factors , preventive measures , and treatment options .", "label": "", "metadata": {}, "score": "99.22984"}
{"text": "Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C .The effect of pegylated ( PEG ) interferon alone or its combination with ribavirin on fibrosis has not been established .", "label": "", "metadata": {}, "score": "100.22445"}
{"text": "February 11 , 2016 , ...As part of their 2015 end of ...Round Table Foundation ( MDRTF ) , has gifted $ 10,000 to University of Chicago to support ovarian ...", "label": "", "metadata": {}, "score": "100.346886"}
{"text": "Contacts : Corporate Paul Westberg SVP Business Development Ph : 650 963 - 8595 Email : Email Contact .Media Debra Bannister Corporate Communications Ph : 530 676 - 7373 Email : Email Contact \" The results of these studies will likely transform the way hematologists treat and manage these conditions , ultimately resulting in improvements in overall patient outcomes such as reducing bruising and unnecessary bleeding that can result if left untreated .", "label": "", "metadata": {}, "score": "101.4802"}
{"text": "February 10 , 2016 , ... Curoverse announced today that ...Arvados provides capabilities for managing and processing genomic and health data at petabyte ... institutions collecting and analyzing genomic data , \" said Adam Berrey chief executive officer at ... .", "label": "", "metadata": {}, "score": "102.07524"}
{"text": "Annals Rheumatic Disease .2012 ; 71(Suppl3):152 .[ 2 ] M Genovese , E Keystone , P Taylor , P - Y Berclaz , C Lee , D Schlichting , S Beattie , M Luchi , W Macias .", "label": "", "metadata": {}, "score": "102.34877"}
{"text": "Annals Rheumatic Disease .2012 ; 71(Suppl3):152 .[ 2 ] M Genovese , E Keystone , P Taylor , P - Y Berclaz , C Lee , D Schlichting , S Beattie , M Luchi , W Macias .", "label": "", "metadata": {}, "score": "102.34877"}
{"text": "If you ca n't find a tool you 're looking for , please click the link at the top of the page to \" Go to old article view \" .", "label": "", "metadata": {}, "score": "103.08699"}
{"text": "Do I hear you say \" But that 's impossible , cirrhosis is n't reversible ! \" If so , this paper and a summary of other studies in the field may help to change your mind .", "label": "", "metadata": {}, "score": "104.220505"}
{"text": "Treatment for thrombocytopenia is dependent on the cause and severity of the condition and can include drug therapy , splenectomy ( removal of spleen , whose function is to breakdown blood cells such as platelets ) , and platelet transfusions .", "label": "", "metadata": {}, "score": "104.492584"}
{"text": "Treatment for thrombocytopenia is dependent on the cause and severity of the condition and can include drug therapy , splenectomy ( removal of spleen , whose function is to breakdown blood cells such as platelets ) , and platelet transfusions .", "label": "", "metadata": {}, "score": "104.492584"}
{"text": "( Date:2/11/2016 ) ... ...February 11 , 2016 , ... Husted Kicking has completed its Third ... February 6th & 7th , 2016 according to kicking coach Michael Husted . , \" This event ... the NFL 's combine in Indianapolis , \" says Husted . \" The NFL uses a third party organization ... .", "label": "", "metadata": {}, "score": "105.40228"}
{"text": "About Diartis Pharmaceuticals Diartis Pharmaceuticals , Inc. is a privately held biopharmaceutical company with headquarters in Redwood City , CA .Diartis develops novel biologics with enhanced properties to provide improved therapeutic outcomes to patients with metabolic diseases .", "label": "", "metadata": {}, "score": "105.552216"}
{"text": "About Diartis Pharmaceuticals Diartis Pharmaceuticals , Inc. is a privately held biopharmaceutical company with headquarters in Redwood City , CA .Diartis develops novel biologics with enhanced properties to provide improved therapeutic outcomes to patients with metabolic diseases .", "label": "", "metadata": {}, "score": "105.552216"}
{"text": "5 ] .About Eli Lilly and CompanyLilly , a leading innovation - driven corporation , is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations .", "label": "", "metadata": {}, "score": "105.998604"}
{"text": "5 ] .About Eli Lilly and CompanyLilly , a leading innovation - driven corporation , is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations .", "label": "", "metadata": {}, "score": "105.998604"}
{"text": "About IncyteIncyte Corporation is a Wilmington , Delaware -based biopharmaceutical company focused on the discovery , development and commercialization of proprietary small molecule drugs for oncology and inflammation .", "label": "", "metadata": {}, "score": "111.75312"}
{"text": "About IncyteIncyte Corporation is a Wilmington , Delaware -based biopharmaceutical company focused on the discovery , development and commercialization of proprietary small molecule drugs for oncology and inflammation .", "label": "", "metadata": {}, "score": "111.75312"}
{"text": "About Rheumatoid ArthritisRheumatoid arthritis is an autoimmune disease that is characterized by inflammation and progressive destruction of joints .[ 4 ] Current treatment of RA includes the use of non - steroidal anti - inflammatory drugs , oral disease - modifying antirheumatic drugs such as methotrexate , and injectable biological response modifiers that target selected mediators implicated in the pathogenesis of RA .", "label": "", "metadata": {}, "score": "112.51649"}
{"text": "About Rheumatoid ArthritisRheumatoid arthritis is an autoimmune disease that is characterized by inflammation and progressive destruction of joints .[ 4 ] Current treatment of RA includes the use of non - steroidal anti - inflammatory drugs , oral disease - modifying antirheumatic drugs such as methotrexate , and injectable biological response modifiers that target selected mediators implicated in the pathogenesis of RA .", "label": "", "metadata": {}, "score": "112.51649"}
{"text": "( Date:2/3/2016 ) ... Calif. , Feb. 3 , 2016 Vigilant ...Police Department in Missouri ... license plate reader ( LPR ) data from Vigilant Solutions . ... hit - and - run case in which the victim was walking out of a convenience ... parking space next to his vehicle , striking his vehicle ... .", "label": "", "metadata": {}, "score": "112.66449"}
{"text": "The show focuses on hematologists as they work to unravel medical mysteries and save lives .SOURCE American Society of Hematology Copyright \u00a9 2008 PR Newswire .", "label": "", "metadata": {}, "score": "113.096504"}
{"text": "The liver disease is usually insidious in onset and most of the morbidity and mortality occur as a direct consequence of the development of liver fibrosis and cirrhosis and later complications .", "label": "", "metadata": {}, "score": "113.106346"}
{"text": "Notice : Wiley Online Library will be unavailable on Saturday 27th February from 09:00 - 14:00 GMT / 04:00 - 09:00 EST / 17:00 - 22:00 SGT for essential maintenance .", "label": "", "metadata": {}, "score": "113.22918"}
{"text": "Disclaimer : AAAS and EurekAlert ! are not responsible for the accuracy of news releases posted to EurekAlert ! by contributing institutions or for the use of any information through the EurekAlert system . 2 Lipids and Diabetes Research Group , Christchurch School of Medicine , Christchurch , New Zealand .", "label": "", "metadata": {}, "score": "114.131714"}
{"text": "Baricitinib , formerly LY3009104 ( INCB28050 ) , is an orally available Janus kinase ( JAK ) inhibitor being studied for use in the treatment of certain autoimmune conditions , including RA .", "label": "", "metadata": {}, "score": "117.90415"}
{"text": "Baricitinib , formerly LY3009104 ( INCB28050 ) , is an orally available Janus kinase ( JAK ) inhibitor being studied for use in the treatment of certain autoimmune conditions , including RA .", "label": "", "metadata": {}, "score": "117.90415"}
{"text": "Unisys Corporation ( NYSE : UIS ) today announced the implementation ...New York City , to help U.S. ... the United States using passports that are ... of the system at Dulles last year .", "label": "", "metadata": {}, "score": "120.973785"}
{"text": "Cirrhosis reversal seems possible in patients with chronic hepatitis C. Editorials Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C Michael J. P. Arthur Liver Group Division of Infection , Inflammation , and Repair University of Southampton Southampton , England .", "label": "", "metadata": {}, "score": "125.30102"}
{"text": "Chronic hepatitis C virus ( HCV ) infection poses a major worldwide health care problem as a leading cause of chronic liver disease and cirrhosis .", "label": "", "metadata": {}, "score": "136.1107"}
